Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07457125 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease

Study acronym: CB-EXOAD
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened
    • Start date: Mar 10, 2026 to May 30, 2026
    • Site details revised
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is divided into two phases: a dose-escalation phase and an expansion cohort phase. The dose-escalation phase is a single-center study, while the expansion cohort phase is a multicenter, prospective, randomized, double-blind, placebo-controlled study.
Trial Details
NCT Number NCT07457125
Lead Sponsor Xuanwu Hospital, Beijing
Collaborators: Carrier Biomed (Suzhou) Co., Ltd, Chinese Academy of Sciences
Conditions
(from sponsor)		 Mild to Moderate Alzheimer's Disease
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov